DrugPatentWatch Database Preview
Drugs in Development Information for Tasisulam
» See Plans and Pricing
What is the drug development status for Tasisulam?
Tasisulam is an investigational drug.
There have been 11 clinical trials for Tasisulam.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2009.
The most common disease conditions in clinical trials are Melanoma, Neoplasms, and Lung Neoplasms. The leading clinical trial sponsors are Eli Lilly and Company and [disabled in preview].
Summary for Tasisulam
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 13 |
| WIPO Patent Applications | 60 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2009-12-01) |
| Vendors | 59 |
Recent Clinical Trials for Tasisulam
| Title | Sponsor | Phase |
|---|---|---|
| A Tasisulam and Midazolam Drug Interaction Study in Cancer Patients | Eli Lilly and Company | Phase 1 |
| A Drug Interaction Study of Tasisulam in Patients With Advanced Cancer or Lymphoma | Eli Lilly and Company | Phase 1 |
| A Study of Tasisulam Versus Paclitaxel as Treatment for Metastatic Melanoma | Eli Lilly and Company | Phase 3 |
Clinical Trial Summary for Tasisulam
Top disease conditions for Tasisulam
Top clinical trial sponsors for Tasisulam
US Patents for Tasisulam
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
